Most patients diagnosed with breast cancer (BC) have hormone receptor (HR+)-positive disease.1 Endocrine therapy (ET) improves survival in HR + early-stage BC (EBC) and metastatic BC (MBC). Here, NR4A1 is linked to breast cancer.